Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 34Leukemia 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Hematologic Neoplasms 4Recurrence 3Neoplasms 2Thrombocytopenia 1Sarcoma, Myeloid 1Sarcoma, Kaposi 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Myeloid 1Immunoproliferative Disorders 1HIV Infections 1Disease 1Congenital Abnormalities 1Acquired Immunodeficiency Syndrome 1

Interventions

venetoclax 1quizartinib 1Daunorubicin 1Cytarabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Sarcoma, Myeloid × Daunorubicin × Clear all
NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡